From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tom Winnifrith Bearcast: Am I wrong about Supply@ME Capital and how do you know if Andrew Prelea of Vast is lying?

By Tom Winnifrith | Thursday 28 October 2021


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I start with a few notes on horticulture here in Wales then move onto questioning my strongly held belief that Supply@ME Capital (SYME) is a worthless fraud. Then I explain why the recent Cenkos note on Skinbiotherapeutics (SBTX) is wrong and how, via its website, the company faces an acid test. Actually the website I refer to has now been amended as you can see HERE. But not before my contact placed an order.  Finally I look at Vast Resources (VAST) and its shocking placing followed by even more shocking no-one is watching O’clock results.

You must be a paid subscriber to listen to Bearcast
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 17:50:23